Riskpilot← Back to searchSign inGet full accessAprivax AB
ABActiveOrg 5595305037Research and experimental development on natural sciences and engineering · NACE 7210Est. 20250 employees
Revenue 2025
—
EBITDA margin
—
Equity ratio
88.8%
Financial strength
Net profit 2025
SEK -28K
0 employees
| Revenue | — | — |
| EBITDA | SEK -28K | — |
| Net profit | SEK -28K | — |
| Total assets | SEK 81K | — |
| Equity | SEK 72K | — |
| Employees | 0 | — |
Legal name
Aprivax AB
Org number
5595305037
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
12 maj 2025
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget sak bedriva bioteknisk forskning och utveckling samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2025 |
|---|---|
| Revenue | — |
| Staff expenses | −2 |
| EBITDA | −28 |
| Depreciation & amort. | — |
| EBIT | −28 |
| Net financials | — |
| Profit before tax | −28 |
| Tax | — |
| Net profit | −28 |
| Item | 2025 |
|---|---|
| Total assets | 81 |
| Equity | 72 |
| Long-term debt | — |
| Short-term debt | 9 |
| Total debt | 9 |
EBITDA margin
-2795800.0%
This company
15.8%
Market median
-17695037% vs market
20252025
Equity ratio
88.8%
This company
38.2%
Market median
+132% vs market
20252025
Return on equity
-38.8%
This company
18.4%
Market median
-311% vs market
20252025
Net profit margin
-2795800.0%
This company
8.1%
Market median
-34516149% vs market
20252025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20252025
Debt / equity
0.13×
This company
0.62×
Market median
+79% vs market
20252025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-05-12 – 2025-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
GC Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2025 | — | — | |
| Chairman | 2025 | — | — | |
| Board of Directors | 2025 | — | — | |
| Deputy Board Member | 2025 | — | — | |
| Deputy Board Member | 2025 | — | — | |
| Board of Directors | 2025 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Aprivax AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Göran Conradson | Chief Executive Officer | 0 companies |
| Carl Philip Anders Franzén | Deputy Board Member | 0 companies |
| Ulf Hans Eskil Söderlind | Chairman | 0 companies |
| Jonas Karl Olof Brambeck | Board of Directors | 0 companies |
| Stina Maria Selldén | Deputy Board Member | 0 companies |
| Erik Alexander Stötsberg | Deputy Board Member | 0 companies |
| Mikaela Jenni Berglund | Board of Directors | 0 companies |